10-K: Callan JMB Reports Deepening Losses Amid Revenue Decline

Callan JMB Inc. reported a significant net loss of $7.97 million for 2025, a substantial increase from the prior year, alongside a 13% drop in revenue.

Summary

• A net loss of $(7,966,366) was incurred for the year ended December 31, 2025, a 247% increase from the $(2,293,648) net loss in 2024.
• Revenue decreased by 13% to $5,723,178 in 2025 from $6,563,412 in 2024, primarily due to reduced demand for emergency preparedness services.
• Gross profit declined by 17% to $2,104,541 in 2025 from $2,563,263 in 2024.
• Selling, general, and administrative expenses surged by 77% to $8,597,032 in 2025 from $4,838,077 in 2024, driven by increased consulting, IT support, and marketing costs related to capital raising and public company operations.
• An impairment charge of $542,088 was recorded on property and equipment in 2025.
• The company has an accumulated deficit of $(10,260,014) as of December 31, 2025.
• Cash used in operating activities was $(4,546,724) in 2025, a significant deterioration from cash provided of $540,353 in 2024.
• Top three customers accounted for approximately 79% of total revenue in 2025 (Customer 1: 58%, Customer 2: 10%, Customer 3: 11%).
• A material weakness in internal control over financial reporting was identified as of December 31, 2025, related to the timeliness and consistency of oversight and governance.
• The company entered into an Equity Line of Credit (ELOC) facility on July 24, 2025, for up to $25 million, with $23.45 million remaining availability as of March 31, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to significant increases in net loss and operating expenses, coupled with a decline in revenue and identified material weaknesses in internal controls, raising going concern doubts despite recent capital raises.

Positives

• Successfully completed an initial public offering (IPO) in February 2025, raising approximately $4.5 million in net proceeds.
• Secured an Equity Line of Credit (ELOC) facility for up to $25 million, providing a potential source of future capital, with $23.45 million remaining availability as of March 31, 2026.
• Management believes that current liquidity sources and strategic initiatives will alleviate substantial doubts regarding the company's ability to continue as a going concern.
• Established strategic alliances with global shipping providers like FedEx, DHL, and UPS, which are expected to drive growth in revenues.
• Possesses strong competitive strengths in emergency response, specialty temperature-regulating reusable packaging, and extensive experience in highly regulated industries.
• Committed to environmental sustainability through the utilization of reusable packaging systems, which helps reduce waste and costs.

Negatives

• Net loss increased by 247% from $(2,293,648) in 2024 to $(7,966,366) in 2025.
• Revenue decreased by 13% in 2025, primarily due to reduced demand for emergency preparedness services and a significant customer temporarily suspending orders.
• Gross profit decreased by 17% in 2025.
• Selling, general, and administrative expenses increased by 77% in 2025, significantly contributing to the increased net loss.
• An impairment loss of $542,088 on property and equipment was recorded in 2025.
• The company has an accumulated deficit of $(10,260,014) as of December 31, 2025.
• Cash used in operating activities significantly increased to $(4,546,724) in 2025 from cash provided of $540,353 in 2024.
• A material weakness in internal control over financial reporting was identified as of December 31, 2025.
• High customer concentration risk, with the top three customers accounting for 79% of revenue in 2025.
• The company's financial statements have been prepared on a going concern basis, but continued net losses and accumulated deficit raise substantial doubt about its ability to continue as a going concern.

Risks

• The company has a holding company ownership structure and depends on distributions from its operating subsidiaries to meet obligations, which could be limited by contractual or legal restrictions.
• The business is capital intensive, requiring ongoing cash outlays that may strain available capital and force asset sales, debt, or unfavorable equity sales.
• Decreased availability or increased costs of key logistics and supply chain inputs, including third-party supplies of equipment and materials, could impact operating costs and profitability.
• Cold chain logistics services face risks and challenges related to environmental, health, safety, and quality control issues, as well as increasing development costs.
• The company may not be able to successfully identify, source, and develop additional warehouse properties in a timely fashion under its rent-to-rent model.
• Inaccurate forecasts of customer demand could lead to excess or obsolete equipment and inventory, harming operating results.
• The company may need to raise substantial additional capital in the future, potentially leading to stockholder dilution or restrictive debt financing covenants.
• The management team has limited experience managing a public company, which could divert attention from day-to-day business operations.
• Future acquisitions of other businesses, products, or technologies may adversely affect the business due to integration difficulties, dilution, or substantial cash usage.
• Failure to maintain effective disclosure controls and procedures and internal control over financial reporting could harm the business and stock price.
• Changes in government regulation, including those from the FDA and state agencies, could adversely affect the business, reputation, and financial condition.
• Reliance on critical information systems, including the Sentry platform, exposes the company to risks of failure, cyberattacks, and data breaches, potentially impacting reputation and revenues.
• Agreements with global shipping providers (FedEx, DHL, UPS) may not result in significant revenue or cash flow increases due to the absence of minimum service requirements.
• The company is subject to income taxes and non-income-based taxes, with potential for adverse outcomes from audits or changes in tax laws.
• As an emerging growth company and smaller reporting company, reduced reporting requirements may make the common stock less attractive to investors.
• Products and services may expose the company to liability in excess of current insurance coverage, particularly when used in human reproductive medicine.
• The use of biological and hazardous materials by customers could lead to liability for damages in case of accidental contamination or injury.
• High customer concentration risk, with a few major customers accounting for a significant percentage of revenue, means the loss of one could materially adversely affect the business.
• Delays or interruptions in shipping due to factors outside of the company's control (e.g., natural disasters, carrier error) could lead to customer dissatisfaction and harm reputation.
• Damage to the company's reputation from negative publicity or product errors/defects could negatively impact business, financial condition, and results of operations.
• Changes in trade policy, tariffs, and import/export regulations may have a material adverse effect on international operations and transactions.
• The company operates in a competitive industry and may not be able to compete effectively against firms with greater resources.
• Difficulty in establishing sales, marketing, and distribution capabilities could hinder revenue growth.
• The CEO and CMO collectively control 62% of the voting power, making the company a 'controlled company' under Nasdaq rules, which may limit stockholder protections.
• The company does not intend to pay dividends for the foreseeable future, meaning capital appreciation is the sole source of gain for stockholders.
• Future sales of a substantial number of common stock or warrants by existing stockholders could cause the stock price to decline.
• The common stock may be subject to penny stock rules in the future, making it more difficult to resell securities.
• Changes in accounting principles and guidance, or their interpretation, could result in unfavorable accounting changes or effects, including changes to previously filed financial statements.

Future Outlook

The company plans to further enhance its sales, marketing, and distribution capabilities in the Americas, EMEA, and APAC, and broaden strategic alliances with shipping service providers to incorporate its platform. It hopes to expand into GLP-1 drug transport, compounding pharmacies, and high-end food packaging, leveraging its Sentry monitoring system to ensure product integrity and safety. Management intends to continue evaluating and utilizing available funding, including operating cash flows, equity or debt financing, and additional funding from Mr. Wayne Williams, to support operations and growth.

Management Comments

• Management believes that these liquidity sources, combined with its plan to explore various strategic initiatives, investment opportunities and cost reduction strategy, will alleviate any substantial doubts regarding the Company’s ability to continue as a going concern.
• Our strategy involves leveraging our core competitive strengths to develop and maintain ongoing relationships with a diversified group of customers while continuing to grow our service lines, ensuring that we can meet our customers changing needs.
• We strive to be recognized as the premier provider of logistics and fulfillment of a broad range of value-added services based upon the breadth of those services, quality, responsiveness, customer service, information technologies, safety, and cost effectiveness.
• We view our solutions as disruptive to the older technologies of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our clients requirements.

Industry Context

StockSavvy.ai notes that Callan JMB operates in the rapidly growing segment of the logistics industry focused on temperature-sensitive packaging and shipping of biological materials. This sector is experiencing increased expenditures for value-added packaging due to globalization and the introduction of pharmaceutical products requiring cryogenic temperatures. The company's focus on passively controlled temperature transport systems and comprehensive tracking aligns with expected global industry standards and regulations for increased reliability and validation of shipping temperatures. The expansion into GLP-1 drug transport and high-end food packaging reflects a strategic move into adjacent markets with similar thermal management needs, capitalizing on broader trends in specialized logistics.

Comparison to Industry Standards

• The company positions its solutions as 'disruptive to the older technologies of dry ice and liquid nitrogen,' suggesting a competitive advantage over traditional methods used by general logistics providers.
• Claims to offer a 'more comprehensive range of services and products than competitors in major portions of the United States and Canada,' implying a broader offering than many national and regional firms.
• The company's 17+ years of experience and reputation for swift emergency response support for Fortune 500 firms, City of Chicago, NATO, and the UN, indicates a strong track record in a demanding, high-stakes environment, potentially exceeding the capabilities of smaller, privately-owned firms.
• Compliance with regulations like VAWD Accreditation, USP 1079/1083, FDA 21 CFR Part 11/210/211 & 820, and ICHQ8/Q10 demonstrates adherence to high industry standards for life sciences logistics, comparable to leading specialized cold chain providers.

Management Changes

Corporate Governance

Legal Proceedings

• Settled a lawsuit with a vendor for $240,800 in February 2025, related to an alleged breach of a Customer Service Agreement. The company initially asserted it owed $85,000.
• Subject to ongoing litigation by a former employee, but management believes material losses are not probable as of December 31, 2025.

Related Party Transactions

• Provided labor services to Health Hero America (HHA), a related party, recognizing $16,789 in service revenue in 2025.
• Pays $9,800 per month to Outlaw Run Ranch (ORR), a related party, for rent expense. The operating lease liability with ORR was $389,630 as of December 31, 2025.
• Leases its headquarters, warehouse, other warehouse equipment, and a box truck from Warehouse Asset Management, a related party, for $15,425 per month. The operating lease liability with Warehouse Asset Management was $625,805 as of December 31, 2025.
• Advanced $18,669 to a director in 2024, which was repaid in full in 2025.
• Awarded 100,000 stock options to the CEO's son in 2025 as compensation for prior services, with 37,500 options vested as of December 31, 2025.
• Reorganization agreement on February 14, 2024, where Coldchain Technology Services, LLC (CTS) members (Wayne Williams and David J. Croyle) exchanged membership interests for 5,000,000 shares of common stock.
• Exchange and Reorganization Agreement on November 14, 2024, where existing stockholders (Wayne Williams and David J. Croyle) exchanged shares at a 0.6 to 1 ratio, reducing outstanding shares to 3,000,000.

Stakeholder Impact

• Shareholders: Significant net losses and accumulated deficit could negatively impact shareholder value. Potential dilution from future equity raises (ELOC facility). Concentration of voting power with CEO and CMO (62%) limits the influence of other shareholders. No dividends are expected in the foreseeable future.
• Employees: The company's growth strategy and focus on technology could create new opportunities. Cybersecurity risks could impact employee data. Stock options and restricted stock units are part of executive and director compensation.
• Customers: Decreased demand for emergency preparedness services led to revenue decline. High customer concentration means the loss of a major customer could severely impact the business. The Sentry monitoring system aims to enhance product integrity and customer satisfaction.
• Suppliers/Vendors: Dependence on third-party supplies and transportation services creates supply chain risks. A lawsuit settlement with a vendor indicates past contractual disputes.
• Creditors: The 'going concern' doubt raises concerns about the company's ability to meet future obligations. The ELOC facility provides a source of capital but also adds to potential future liabilities.

Next Steps

• Continue to develop and refine disclosure controls and procedures.
• Remediate the identified material weakness in internal control over financial reporting by enhancing oversight, improving documentation, and engaging third-party advisors.
• Further enhance sales, marketing, and distribution capabilities in the Americas, EMEA, and APAC.
• Broaden strategic alliances with domestic and international providers of shipping services.
• Explore expansion into GLP-1 drug transport, compounding pharmacies, and high-end food packaging.
• Continue evaluating and utilizing available funding, including operating cash flows, equity or debt financing, and additional funding from Mr. Wayne Williams.
• The 2024 Plan administrator will determine the number of shares for annual increase, up to 500,000 shares or 4% of prior year's maximum.
• The Compensation Committee will review and recommend the compensation of the CEO and other executive officers annually.
• The Compensation Committee will review and establish general policies relating to compensation and benefits of employees.
• The Compensation Committee will review and evaluate succession plans for executive officers.
• The Nominating and Corporate Governance Committee will annually review the composition of the board of directors.
• The Nominating and Corporate Governance Committee will develop and make recommendations regarding corporate governance guidelines.
• The Nominating and Corporate Governance Committee will oversee periodic evaluations of the board's performance.
• The company will file tax returns in the United States and various states.
• The company will continue to monitor and assess the impact of the Tax Cuts and Jobs Act.
• The company is evaluating the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) and ASU 2025-05 (Measurement of Credit Losses for Accounts Receivable and Contract Assets).
• The company is evaluating the impact of ASU 2025-11 (Interim Reporting – Narrow-Scope Improvements).

Key Dates

Recommendation

The company reported a substantial increase in net loss and a decline in revenue, indicating deteriorating financial performance. The significant increase in operating expenses, coupled with an impairment loss and a material weakness in internal controls, raises serious concerns about operational efficiency and financial management. The accumulated deficit and the 'going concern' warning from auditors highlight fundamental solvency issues. While the ELOC facility provides some capital, the underlying business performance is weak, and high customer concentration adds to the risk profile. These factors suggest a high-risk investment with significant downside potential, warranting a strong sell recommendation.

Keywords

cold chain logistics, thermal management, life sciences logistics, emergency preparedness, specialty packaging, Sentry monitoring, biopharmaceuticals, cryogenic transport, SEC filing, 10-K, financial results, net loss, revenue decline, capital raise, corporate governance, risk factors, Nasdaq Capital Market, CJMB, going concern